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Sir,
Worldwide, most multiply antibiotic-resistant (MAR), and particu-
larly carbapenem-resistant, Acinetobacter baumannii causing
infections belong to global clone 1 (GC1) or global clone 2 (GC2).
Though there have been incidences where a different clonal group
was predominantly responsible for an epidemic outbreak, MAR
isolates that are not members of these clones have been observed
to cause infections in hospitals but are not as common.1
Isolate D46, collected at Royal North Shore Hospital, Sydney
in 2010, was shown to be resistant to ampicillin, imipenem,
meropenem, ticarcillin/clavulanate, ceftazidime, cefotaxime,
streptomycin, spectinomycin, sulfamethoxazole, tetracycline, tri-
methoprim, chloramphenicol, florfenicol, kanamycin, neomycin,
gentamicin, amikacin, tobramycin, nalidixic acid and ciprofloxa-
cin, making it extensively antibiotic resistant. D46 was previously
shown to be ST110 (Oxford MLST) and to harbour the aphA6 ami-
kacin resistance gene within TnaphA6 and an aadB gene cassette
(gentamicin, kanamycin and tobramycin resistance) in the
small plasmid pRAY.2 An ISAba1 upstream of the chromosomal
ampC confers resistance to third-generation cephalosporins,
ceftazidime and cefotaxime.3
Here, we have further examined the causes of resistance. Using
PCR as described previously,4 D46 was shown to contain the
strA-strB, sul2 and tetA(B) genes, responsible for streptomycin,
sulfamethoxazole and tetracycline resistance, respectively. These
genes were in the same configuration as in AbGRI1-2 (Tn6167),4
but D46 does not have an island in comM. Carbapenem and
ticarcillin/clavulanate resistance was due to the blaOXA-23 carba-
penemase gene, which was within Tn2006.
To better understand how Tn2006 was acquired, conjugation
was performed as described previously,5,6 using D46 as a donor
and a rifampicin-resistant mutant of A. baumannii ATCC 17978
as a recipient. Transconjugants resistant to meropenem, imipe-
nem and ticarcillin/clavulanate, indicative of blaOXA-23, and resist-
ant to kanamycin, neomycin and amikacin, indicative of aphA6,
were recovered. Hence, both Tn2006 and TnaphA6 were located
on a conjugative plasmid.
The whole genome sequence of D46 was determined using
Illumina HiSeq and assembled as described previously.5 The
draft genome comprised 115 contigs with an average read
depth of 88.7× coverage and D46 was determined to be ST25
according to the Pasteur MLST scheme. Three plasmids were
detected. The sequence of the smallest plasmid, pD46-1
(6078 bp), contained aadB and was almost identical to pRAY* (a
single base difference).2 pD46-2 is an 8731 bp cryptic plasmid
that was identical to p1ABTCDC0715 (GenBank accession number
CP002523) from a GC2 isolate.
To determine whether D46 harboured Tn2006 together with
TnaphA6 on a plasmid related to pAb-G7-25 and pD72-2,7 contigs
that matched them were retrieved from the draft genome. Seven
contigs were recovered and assembled using PCR.5,7 The ampli-
cons were sequenced, finalizing the assembly. Plasmid pD46-3
has a 67027 bp backbone sharing 99.99% identity (five single-
base changes) with that of pD72-2 (Figure 1a). pD46-3 also
harboured TnaphA6 in the same position as pD72-2 (Figure 1a).
One end of two backbone contigs had inversely oriented frag-
ments of ISAba1 and they were linked with blaOXA-23 in Tn2006
using PCR (Figure 1a). The complete 74 916 bp sequence of
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pD46-3 was deposited in GenBank under accession number
KM977710. As the backbone of pD46-3 was almost identical
to that of pD72-2 and pAb-G7-2, pD46-3 also contained the
complete set of transfer genes (Figure 1). This is the first report
of a completely sequenced A. baumannii plasmid that has been
demonstrated to simultaneously transfer resistance to carbape-
nems and aminoglycosides.
A recent genomic study of a GC2A. baumannii collection from a
US hospital reported the sequence of pABUH1 (GenBank accession
number AYOH01000010), which the authors suggested could be
transferable.8 It was described as a plasmid related to pACICU2,
harbouring ISAba1 upstream of aphA6 and having a copy of
blaOXA-23 flanked by two copies of ISAba125 that is in the same
position as ISAba125 in pACICU2.8 However, it was recently
shown that pACICU2 is likely identical to pAb-G7-2 and in fact
harbours TnaphA6 at this location.9 Our analysis of the sequence
of pABUH1 revealed that it in fact carries TnaphA6 in this position
(Figure 1b). Furthermore, ISAba1 is actually upstream of blaOXA-23,
in a structure similar to Tn2008 (GenBank accession number
GQ861438) that is flanked by a 9 bp direct repeat. However, in
pABUH1 the sequence adjacent to the ISAba1 was 1613 bp
whereas it is only 1351 bp in Tn2008.
The backbones of the repAci6 plasmids, pAb-G7-2, pD72-2,
pD46-3, pABUH1 and pACICU2, are all very closely related, but
they can be separated into two lineages based on the position
of TnaphA6 (Figure 1). Representatives of the two lineages,
pD46-3 and pABUH1, have each acquired the blaOXA-23 gene on
separate occasions and a sixth repAci6 plasmid, pA85-3, has
also gained blaOXA-23 within AbaR4.
6 The acquisition of blaOXA-23
in different structures and in separate events indicates
that this group of related plasmids plays a vital role in the dis-
semination of this carbapenemase gene and could be one of
the factors responsible for making it a worldwide problem.
Hence, surveillance of this group of A. baumannii plasmids will
be vital in curtailing the spread of carbapenem resistance in A.
baumannii.
(a)
(b)
Figure 1. Comparison of repAci6 plasmids pD72-2, pD46-3 (a), pABUH1 and pAb-G7-2 (b). The plasmid backbones, linearized and opened at repA, are
represented by horizontal lines. The extent of ORFs and genes are shown as arrows beneath the lines, with names given where a function is known. The
transfer region is indicated above each line, the tra genes are indicated with capital letters and trbC is shown as c. The three repeat regions are indicated
by the numbered boxes. The structures of TnaphA6, Tn2006 and Tn2008-like are shown above or below the backbone, with IS represented as open boxes
containing an arrow showing their orientation.
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Sir,
Fosfomycin [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid is a
broad-spectrum antibiotic with bactericidal activity against both
Gram-positive and Gram-negative bacteria.1 Fosfomycin inhibits
bacterial cell wall synthesis by inactivating the enzyme UDP-
N-acetylglucosamine-3-enolpyruvyl transferase (MurA), which is
essential for the catalysis of bacterial peptidoglycan biosynthesis.
Thus, modification or overexpression of MurA can contribute to
the development of fosfomycin resistance in bacteria.2 Other
common mechanisms of resistance to fosfomycin include
decreased drug uptake and inactivation of the antibiotic by add-
ition of various groups.3 To date, several fosfomycin resistance
genes have been functionally characterized in bacteria. FomA
and FomB enzymes can inactivate fosfomycin by phosphoryl-
ation.4 FosA, FosB and FosX can inactivate fosfomycin by catalys-
ing the addition of glutathione, L-cysteine and H2O, respectively,
to its epoxide ring.2
Campylobacter species are the leading foodborne patho-
gens worldwide, accounting for 400 –500 million cases of diar-
rhoea each year.5 Over the past few decades, Campylobacter
species have become increasingly resistant to several clinically
important antimicrobial agents, compromising the effective-
ness of clinical therapy.6 Various mechanisms of resistance to
macrolides, fluoroquinolones, tetracyclines, aminoglycosides
and b-lactams in Campylobacter have been extensively
described.7 In addition, clinical trials have indicated that fosfo-
mycin can effectively treat Campylobacter enteritis in
humans.8 To date, no mechanism of fosfomycin resistance
has been characterized in Campylobacter species. Here, we
identified a novel fosX-like gene from Campylobacter coli
(designated fosXCC), located in the multidrug resistance gen-
omic island (MDRGI), which confers fosfomycin resistance to
Campylobacter species.
C. coli DZB4 was isolated from swine faeces in China in
2012. Our recent study indicated that DZB4 contains a type II
MDRGI consisting of 10 ORFs that is inserted between cadF
and CCO1582 on the chromosome (GenBank accession number
KC876749) and this MDRGI can mediate antibiotic resistance,
at least to macrolides, aminoglycosides and tetracycline.9
Further analysis revealed that the fifth ORF, immediately
upstream of erm(B), in type II MDRGI encodes a 136 amino
acid protein that exhibits 26.9%, 34.2% and 63.9% identity to
fosfomycin resistance determinants FosA, FosB and FosX found
in Serratia marcescens (M85195),10 Staphylococcus haemolyticus
(X89875)11 and Listeria monocytogenes (NP_465227.1),2
respectively. Protein structure prediction indicated that this
putative protein has identical quaternary structure to FosX and
contains the conserved active site residue E44, which plays a
key role in catalysis in FosX but not in FosA or FosB.2,12,13
Considering that the fosfomycin MIC for isolate DZB4 was
.512 mg/L, which is much higher than that for reference strains
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